References
- Kmiec Z. Cytokines in inflammatory bowel disease. Arch Immunol Ther Exp (Warsz) 1998; 46: 143–55
- Lisciandrano D, Ranzi T, Carrassi A, Sardella A, Campanini MC, Velio P, et al. Prevalence of oral lesions in inflammatory bowel disease. Am J Gastroenterol 1996; 91: 7–10
- Basu MK, Asquith P. Oral manifestations of inflammatory bowel disease. Clin Gastroenterol 1980; 9: 307–21
- Nielsen OH, Vainer B, Madsen SM, Seidelin JB, Heegaard NH. Established and emerging biological activity markers of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 359–67
- Jørgensen LGM, Fredholm L, Petersen PH, Hey H, Munkholm P, Brandslund I. How accurate are clinical activity indices for scoring of disease activity in inflammatory bowel disease (IBD). Clin Chem Lab Med 2005;43:403–411.
- Larsen TB, Nielsen JN, Fredholm L, Lund ED, Brandslund I, Munkholm P, et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 2002; 32: 92–6
- Grottrup-Wolfers E, Moeller J, Karbach U, Muller-Lissner S, Endres S. Elevated cell-associated levels of interleukin 1β and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur J Clin Invest 1996; 26: 115–22
- Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, et al. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174–81
- Mazlam MZ, Hodgson HJF. Interrelations between interleukin-6, interleukin-1β, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994; 35: 77–83
- Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74–80
- Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol 1998; 16: 249–84
- Bendtzen K, Hansen PR, Rieneck K, the Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-α and interferon-γ, and has potential in the treatment of arthritis. Clin Exp Immunol 2003; 134: 151–8
- Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index: national cooperative Crohn's disease study. Gastroenterology 1976; 70: 439–44
- Seo M, Okada M, Yao T, Ueki M, Arima S, Okumura M. An index of disease activity in patients with ulcerative colitis. Am J Gastroenterol 1992; 87: 971–6
- Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim M, et al. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 1999; 94: 2156–64
- Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, et al. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351–9
- Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease. J Clin Gastroenterol 1995; 20: 123–6